Our positions

We use our evidence-based policy positions to inform our campaigning work and to respond to public consultations relating to prostate cancer care. We aim to inform and influence policy development to improve prostate cancer services and care.

Pre Chemotherapy Abiraterone

Abiraterone (Zytiga┬«) is a new type of hormone therapy. It is suitable for men whose prostate cancer has spread to other parts of the body (advanced prostate cancer) and has stopped responding to other hormone therapy treatments. The use of abiraterone post chemotherapy has already been approved for use on the NHS throughout the UK. However, the use of abiraterone before a man has received chemotherapy has yet to be approved on the NHS. Read our full policy position.

Cabazitaxel

Cabazitaxel is a drug which can help extend the lives of men with advanced prostate cancer who have stopped responding to hormone therapy and docetaxel based chemotherapy. It was rejected by the National Institute for Health and Care Excellence (NICE) and the Scottish Medical Consortium (SMC) due to concerns over side effects which may impact on a man's quality of life and also the cost of the drug. Read our full policy position.

Cancer Drugs Fund

The Cancer Drugs Fund (CDF) enables English cancer patients to apply for funding for drugs which can be prescribed but not approved for use on the NHS by the NICE. The fund will end in 2014. It is likely to be replaced by Value Based Pricing (VBP), which will cover all new medicines from 2014. Read our full policy position.

Early diagnosis and detection

Early diagnosis means the early detection of cancer. This should lead to benefits in survival if it involves in the diagnosis of disease at an earlier, more treatable stage, and that effective treatment for the disease exists. The National Awareness and Early Diagnosis Initiative (NAEDI), a public sector/third sector partnership with the Department of Health, has been established in England to improve overall cancer outcomes.  Read our full policy position.

Information

Information in this context means any information given to men to help them understand prostate cancer and its treatment. Information can take many different forms. It is essential that written information is provided in a clear and accessible manner and in languages other than English where necessary. Read our full policy position.

Quality performance indicators (Scotland only) 

Quality Performance Indicators (QPIs) are a set of standards used to measure and monitor cancer related data in Scotland.  Read our full policy position.

NICE Quality Standard for prostate cancer  

NICE quality standards are a concise set of statements designed to drive and measure priority and quality improvements within a particular area of care. The quality standard for prostate cancer has been delayed until at least the end of 2014. Prostate cancer is the only major tumour type not to have a quality standard published, or in development. Read our full policy position.

Robotic surgery

Robotic surgery is keyhole surgery performed by a special machine to remove the prostate gland (a prostatectomy), operated by a surgeon. Read our full policy position.

PSA test

The prostate specific antigen (PSA) test is a blood test used to detect prostate cancer. There are, however, problems with the reliability of the PSA test. Many men receive 'false positive' and 'false negative' results which cause them unnecessary anxiety or false reassurance.  Read our full policy position.

Specialist nurses

Specialist nurses provide expert care and support to people with a wide range of conditions in the UK such as cancer, asthma, heart disease and multiple sclerosis. Prostate cancer specialist nurses provide invaluable support in the form of information and managing complex and challenging side effects. Read our full policy position.

Use of animals in research

In common with most medical research charities, we acknowledge that, despite developments in areas such as cell culture and computer modelling, there will be times when research still depends on the use of animals. Following guidance from the Association of Medical Research Charities and the Home Office, we will not fund animal research unless it is essential and there is no alternative.

Find out more about the research we fund.